Pharma-Bio Serv (PBSV) Non-Current Debt (2020 - 2021)
Pharma-Bio Serv (PBSV) reported Non-Current Debt of $643900.0 for Q2 2021, down 50.0% year-over-year from $1.3 million in Q2 2020, and little changed on a QoQ basis from $643900.0 in Q1 2021.
Pharma-Bio Serv (PBSV) Non-Current Debt (2020 - 2021) Analysis & Trends
Pharma-Bio Serv's Non-Current Debt history runs 2 years deep, the most recent figure standing at $643900.0 for Q2 2021.
- Non-Current Debt for Q2 2021 came in at $643900.0, down 50.0% year-over-year; the trailing twelve-month figure through Apr 2021 was $643900.0 (down 50.0% YoY), and the FY2020 annual result was $643900.0, changed N/A from the prior year.
- Non-Current Debt came in at $643900.0 for Q2 2021 at Pharma-Bio Serv, roughly flat from $643900.0 in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $1.3 million in Q2 2020 to a low of $643900.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Veeva Systems | 24.83 Bn | 17.52 Bn | 662.02 Mn | - |
| 2 | BrightSpring Health Services | 13.57 Bn | 12.69 Bn | 482.22 Mn | 2.44 Bn |
| 3 | Healthequity | 7.20 Bn | 6.93 Bn | 256.31 Mn | 942.66 Mn |
| 4 | Hinge Health | 5.42 Bn | 5.11 Bn | 154.23 Mn | - |
| 5 | 10x Genomics | 4.46 Bn | 3.92 Bn | 106.18 Mn | - |
| 6 | Doximity | 3.81 Bn | 3.06 Bn | 125.97 Mn | - |
| 7 | Waystar Holding | 3.52 Bn | 3.36 Bn | 268.04 Mn | 1.46 Bn |
| 8 | Privia Health | 2.94 Bn | 2.57 Bn | 595.71 Mn | - |
| 9 | Omnicell | 1.76 Bn | 1.59 Bn | 140.36 Mn | - |
| 10 | Pharma-Bio Serv | - | - | 902,041.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2021 | 643,900.00 |
| Apr 30, 2021 | 643,900.00 |
| Jan 31, 2021 | 643,900.00 |
| Jan 31, 2021 | 643,900.00 |
| Oct 31, 2020 | 643,900.00 |
| Oct 31, 2020 | 643,900.00 |
| Jul 31, 2020 | 965,850.00 |
| Jul 31, 2020 | 965,850.00 |
| Apr 30, 2020 | 1.29 Mn |
| Apr 30, 2020 | 1.29 Mn |